

Luminari CRO Announces Addition of Ramzi Dagher, MD

Experienced Physician and Drug Development Leader Joins Luminari CRO as Company Expands Its AI-Driven Approach to Pharmaceutical Development

MIAMI, FL, UNITED STATES, October 8, 2026 /EINPresswire.com/ -- Miami, FL – October 8, 2026 - [Luminari CRO](#) today announced the addition of Ramzi Dagher, MD to its team as a strategic advisor. Dr. Dagher brings extensive experience in oncology, clinical drug development, regulatory science, and pharmaceutical research to Luminari CRO as the company continues to advance the application of artificial intelligence and data-driven approaches across the drug development lifecycle.



Dr. Dagher's career spans medicine, clinical research, regulatory science, and the biopharmaceutical industry. His experience includes work with the U.S. Food and Drug Administration and the National Cancer Institute, as well as leadership roles within the pharmaceutical industry. His work has included oncology drug development, clinical research, regulatory strategy, and the evaluation of emerging therapies.

"Ramzi brings something extremely valuable to Luminari CRO, the combination of medical expertise, drug development experience, and a deep understanding of how science ultimately becomes a therapy for patients," said Yuri Zamostin, CEO of Luminari CRO. "As AI becomes increasingly important in pharmaceutical development, we believe that technology must be grounded in real-world scientific and clinical expertise. Dr. Dagher is an excellent addition to our team as we pursue that vision."

Bringing Clinical and Scientific Expertise to AI-Driven Drug Development

The pharmaceutical industry is entering a period in which artificial intelligence has the potential to reshape how drugs are discovered, developed, evaluated, and brought to patients. However, successful implementation requires more than sophisticated algorithms.

It requires an understanding of biology, medicine, clinical development, regulatory strategy, scientific data, and the decisions that development teams make throughout the lifecycle of a therapeutic program.

Dr. Dagher's experience provides Luminari with an important perspective as the company develops AI-enabled approaches designed to address complex challenges in pharmaceutical development.

"AI has enormous potential in drug development, but the technology is only part of the equation," said Dr. Ramzi Dagher. "The real opportunity is to combine AI with the scientific, clinical, and regulatory knowledge that already exists within our industry. When those capabilities are brought together effectively, we can create new ways of analyzing information, supporting decisions, and improving the efficiency of development."

Dr. Dagher to Make Industry Debut as a Strategic Advisor with Luminari CRO at [Paperless Lab Academy®](#)

Ramzi will make his first public appearance representing Luminari CRO at the Paperless Lab Academy® USA Conference, taking place October 12–14, 2026, in Cambridge, Massachusetts.

Luminari CRO is a sponsor of the event, and Dr. Dagher will participate as an attendee, sharing his perspective on the intersection of AI, pharmaceutical development, scientific data, and clinical decision-making.

His participation at the Paperless Lab Academy® provides an opportunity for the scientific informatics community to engage directly with a physician and drug-development leader who brings perspectives from across the pharmaceutical development ecosystem.

"Scientific informatics is no longer simply about managing scientific information," added Zamostin. "It is increasingly about connecting data, science, people, and decisions. Dagher's experience across medicine, drug development, and regulatory science gives us an important perspective on that evolution."

About Ramzi Dagher, MD

Ramzi Dagher, MD is a physician and drug development professional with experience spanning oncology, clinical research, regulatory science, and the pharmaceutical industry. His career has included work with the U.S. Food and Drug Administration and the National Cancer Institute, along with pharmaceutical-industry leadership and research activities.

Dr. Dagher has contributed to the development and evaluation of therapies in oncology, infectious diseases and other disease areas and has published on drug development and regulatory topics. His multidisciplinary background bridges clinical medicine, scientific research, pharmaceutical development, and regulatory considerations.

About Luminari CRO

Luminari CRO combines pharmaceutical development expertise, technology, and artificial intelligence to address complex challenges across the drug development lifecycle. The company

focuses on applying AI and data-driven approaches to improve development processes, decision-making, and operational efficiency while maintaining the scientific and regulatory rigor required in pharmaceutical development.

Media Contact:

Yuri Zamostin, CEO
Luminari CRO
+1 866-298-9696

This press release can be viewed online at: <https://www.einpresswire.com/article/947974364>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.